BBIO
BRIDGEBIO PHARMA INC
Latest close $82.07 as of Aug 4, 2026
Schedule 13G/13D reports beneficial ownership at an observation date. “Accumulation” or “reduction” is inferred
from changes in reported shares when available; it is not a list of individual trades or exact execution prices.
Form 13F rows are quarter-end holding context only and do not establish an exact entry date.
Free access includes current parsed ownership filings, reported share changes, and ownership-percentage changes.
Significance scoring, disclosure-speed analysis, confirmation/divergence signals, and signal alerts require Investor or Pro.
Compare plans.
Beneficial ownership filing history
Showing 3 of 5 parsed filing(s) · 2 older require more history access| Holder | Observed / filed | Reported change | Shares | Ownership | Observation | Filing | Latest |
|---|---|---|---|---|---|---|---|
| BlackRock CIK0002012383 | Jun 30, 2026 observed Jul 27, 2026 filed · 27d Schedule 13G amendment | Reported reduction | 9.7M -3.1M | 12.00% +5.20 pts | $74.48 | $84.12 | $82.07 |
| BlackRock CIK0002012383 | Sep 30, 2024 quarter end Nov 13, 2024 filed Form 13F quarter-end evidence | Earlier Form 13F quarter-end holding Quarter-end holding evidence; no ownership percentage or signal. | 12.9M | $82.07 | |||
| BlackRock CIK0002012383 | Sep 30, 2024 observed Nov 12, 2024 filed · 43d Schedule 13G amendment | Reported shares unchanged | 12.9M 0 | 6.80% 0.00 pts | $24.62 | $82.07 |